High BMI Associated with Improved OS Following Atezolizumab in Advanced NSCLC Treatment

A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.

Source: CancerNetwork - January 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news